Abiraterone acetate: in metastatic castration-resistant prostate cancer.

Abstract:

:Oral abiraterone acetate, in combination with prednisone/prednisolone, is used to treat patients with metastatic castration-resistant prostate cancer (CRPC) who have previously received docetaxel-containing chemotherapy. Abiraterone acetate was developed to specifically inhibit cytochrome P450 (CYP)17A1, which is an essential enzyme in the biosynthesis of testosterone. In a pivotal phase III trial in patients with metastatic CRPC who have previously received docetaxel-containing chemotherapy, abiraterone acetate 1000 mg once daily plus prednisone 5 mg twice daily significantly prolonged overall survival compared with placebo plus prednisone. In this trial, abiraterone acetate plus prednisone was significantly more effective than placebo plus prednisone in prolonging the time to prostate-specific antigen (PSA) progression and in prolonging progression-free survival. Significantly more abiraterone acetate plus prednisone recipients than placebo plus prednisone recipients were considered to be responders, when assessed by PSA levels or radiographic imaging. Treatment with abiraterone acetate plus prednisone in the phase III trial was associated with an acceptable tolerability profile, which was generally similar to that of the placebo plus prednisone group. However, adverse events of special interest (e.g. cardiac disorders and liver-function test abnormalities and adverse events resulting from elevated mineralocorticoid levels because of CYP17A1 inhibition [i.e. fluid retention and oedema, hypokalaemia, hypertension]) occurred in significantly more abiraterone acetate plus prednisone than in placebo plus prednisone recipients.

journal_name

Drugs

journal_title

Drugs

authors

Yang LP

doi

10.2165/11208080-000000000-00000

subject

Has Abstract

pub_date

2011-10-22 00:00:00

pages

2067-77

issue

15

eissn

0012-6667

issn

1179-1950

pii

7

journal_volume

71

pub_type

杂志文章

相关文献

DRUGS文献大全
  • Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future.

    abstract::Coronary artery disease and acute myocardial infarction still represent the leading cause of mortality in developed countries. Therefore, great efforts have been made in the last decades to improve reperfusion strategies and adjunctive antithrombotic therapies. In fact, despite optimal epicardial recanalisation, a lar...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0425-7

    authors: De Luca G,Savonitto S,van't Hof AW,Suryapranata H

    更新日期:2015-07-01 00:00:00

  • [Atenolol/nifedipine combination: efficacy and tolerability of low dose synergistic bitherapy in the treatment of arterial hypertension].

    abstract::During recent decades, undeniable progress has been made with regard to the management of arterial hypertension. Larger numbers of patients are aware they have hypertension, receive treatment and benefit from this therapy. Furthermore, significant reductions have been observed in morbidity and mortality resulting from...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856002-00004

    authors: Krivitzky A,Nguyen G,Gaudouen Y,Legrand M,Cohen R

    更新日期:1998-01-01 00:00:00

  • Levocetirizine: a review of its use in the management of allergic rhinitis and skin allergies.

    abstract::Levocetirizine (Xyzal) is a selective, potent, oral histamine H(1) receptor antagonist of the latest generation that is licensed for the symptomatic treatment of allergic rhinitis (including persistent allergic rhinitis [PER]) and chronic idiopathic urticaria (CIU). Large, well designed trials indicate that levocetiri...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666070-00017

    authors: Hair PI,Scott LJ

    更新日期:2006-01-01 00:00:00

  • Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.

    abstract::Echinocandins are a new class of antifungal agents with a novel mechanism of action (interference with fungal cell wall synthesis). Caspofungin (Cancidas), Caspofungin MSD) is the first echinocandin to be approved and is administered intravenously. Caspofungin 50 mg/day had similar efficacy to intravenous fluconazole ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363200-00008

    authors: Keating G,Figgitt D

    更新日期:2003-01-01 00:00:00

  • Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension.

    abstract::A once-daily preservative-free fixed combination ophthalmic solution containing tafluprost 0.0015 % and timolol 0.5 % (hereafter referred to as tafluprost/timolol) [Taptiqom(®)] has been developed to lower intraocular pressure (IOP) whilst avoiding damage to the ocular surface associated with preservatives such as ben...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0476-9

    authors: Hoy SM

    更新日期:2015-10-01 00:00:00

  • Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease.

    abstract::Budesonide is a glucocorticoid with high topical activity, but low systemic bio-availability which results in reduced systemic effects in comparison with other glucocorticoids. To date, it has been evaluated for use in patients with inflammatory bowel disease when administered either orally as a controlled ileal relea...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199550050-00006

    authors: Spencer CM,McTavish D

    更新日期:1995-11-01 00:00:00

  • Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients.

    abstract::The antihypertensive effects of the regular immediate release formulation of verapamil (verapamil IR) and the newer sustained release formulation of verapamil (verapamil SR) were compared in Hispanic patients with untreated essential hypertension. Verapamil IR was given in 3 divided doses (80 or 160mg 3 times daily) a...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-199200441-00002

    authors: Fuenmayor NT,Faggin BM,Cubeddu LX

    更新日期:1992-01-01 00:00:00

  • Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments.

    abstract::Non-insulin-dependent diabetes mellitus (NIDDM, type 2 diabetes) is a heterogeneous disease resulting from a dynamic interaction between defects in insulin secretion and insulin action. There are various pharmacological approaches to improving glucose homeostasis, but those currently used in clinical practice either d...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199754030-00001

    authors: Scheen AJ

    更新日期:1997-09-01 00:00:00

  • Correction to: Deprescribing Opioids in Chronic Non‑cancer Pain: Systematic Review of Randomised Trials.

    abstract::Page 9, Fig. 2, which originally appeared as. ...

    journal_title:Drugs

    pub_type: 已发布勘误

    doi:10.1007/s40265-020-01416-7

    authors: Mathieson S,Maher CG,Ferreira GE,Hamilton M,Jansen J,McLachlan AJ,Underwood M,Lin CC

    更新日期:2020-10-01 00:00:00

  • Overview of the worldwide problem of diarrhoea.

    abstract::Acute infectious diarrhoea is the major killer of children in the Third World. It is also the principal cause of malnutrition in children under 5 years of age. More than 4 million children die each year of diarrhoea and its complications. Acute diarrhoea kills by causing dehydration, which leads to hypovolaemia and me...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198800364-00003

    authors: Gold R

    更新日期:1988-01-01 00:00:00

  • Osteoarthritis 1991. Current drug treatment regimens.

    abstract::Osteoarthritis, the most common rheumatic disease, presents the clinician with a major therapeutic and management task. The chronic and progressive course of the disease is punctuated by pain, declining function and escalating disability. This article attempts to deal with the pharmacological therapeutic options avail...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199141020-00005

    authors: al Arfag A,Davis P

    更新日期:1991-02-01 00:00:00

  • Remifentanil: a review of its use during the induction and maintenance of general anaesthesia.

    abstract::Remifentanil (Ultiva), a fentanyl derivative, is an ultra-short acting, nonspecific esterase-metabolised, selective mu-opioid receptor agonist, with a pharmacodynamic profile typical of opioid analgesic agents. Notably, the esterase linkage in remifentanil results in a unique and favourable pharmacokinetic profile for...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565130-00007

    authors: Scott LJ,Perry CM

    更新日期:2005-01-01 00:00:00

  • Dapoxetine: in premature ejaculation.

    abstract::Dapoxetine, a selective serotonin reuptake inhibitor, is the first oral pharmacological agent indicated for the treatment of men aged 18-64 years with premature ejaculation. In four randomized, double-blind, placebo-controlled, multicentre studies of 12-24 weeks' duration, oral dapoxetine 30 or 60 mg (administered as ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11204750-000000000-00000

    authors: Hoy SM,Scott LJ

    更新日期:2010-07-30 00:00:00

  • [The kidney as a target organ in diabetic patients with arterial hypertension].

    abstract::Diabetes mellitus has become the most common single cause of end-stage renal disease in the Western world. Diabetic nephropathy, as most forms of renal disease leading to end-stage renal failure, is frequently complicated by arterial hypertension. In type 1 diabetes mellitus the reported excess in arterial hypertensio...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:

    authors: Viberti G

    更新日期:2003-01-01 00:00:00

  • Somatropin (Zorbtive): in short bowel syndrome.

    abstract::A somatropin preparation (Zorbtive) produced by recombinant DNA technology has been evaluated in patients with short bowel syndrome. Somatropin is thought to enhance intestinal adaptation in this condition through direct or indirect effects on the intestine. In a randomised, double-blind study in patients with short b...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464120-00008

    authors: Keating GM,Wellington K

    更新日期:2004-01-01 00:00:00

  • What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections?

    abstract::The newest (third generation) fluoroquinolones are potentially useful agents in the management of community-acquired respiratory tract infections. This is mainly due to their increased activity against Streptococcuspneumoniae, a pathogen poorly susceptible to the second-generation compounds, and playing a major role i...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199957060-00002

    authors: Momméja-Marin H,Carbon C

    更新日期:1999-06-01 00:00:00

  • 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.

    abstract::In the mid-1980s it was discovered that serotonin (5-hydroxytryptamine; 5-HT) was at least partially responsible for producing chemotherapy-induced nausea and vomiting. It was therefore realised that serotonin receptor blockade with serotonin 5-HT3 receptor antagonists could inhibit chemotherapy-induced nausea and vom...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199855020-00002

    authors: Gregory RE,Ettinger DS

    更新日期:1998-02-01 00:00:00

  • Correction to: Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.

    abstract::The article Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection, written by Emma D. Deeks, was originally published Online First without open access. After publication in volume 78, issue 17, pages 1817-1828 Gilead Sciences requested that the article be Open Choice to make the article an open ...

    journal_title:Drugs

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40265-019-01101-4

    authors: Deeks ED

    更新日期:2019-04-01 00:00:00

  • Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes.

    abstract::Developments in drug delivery technology have expanded the formulations of 5-aminosalicylic acid (5-ASA) available to clinicians over the last 50 years. Delivery of adequate doses of 5-ASA to the colon can be achieved by pH-dependent, delayed-release or pro-drug formulations. Despite some variations in the pharmacokin...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868080-00006

    authors: Fernandez-Becker NQ,Moss AC

    更新日期:2008-01-01 00:00:00

  • Acitretin. A review of its pharmacology and therapeutic use.

    abstract::Acitretin (etretin), a second generation monoaromatic retinoid for use in the treatment of severe psoriasis and other dermatoses, is the major active metabolite of etretinate and possesses a similar therapeutic index; i.e. a similar ratio of clinical efficacy to adverse effects. When used alone at a maintenance dosage...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199243040-00010

    authors: Pilkington T,Brogden RN

    更新日期:1992-04-01 00:00:00

  • Endothelial function. General considerations.

    abstract::The endothelium is involved in both the physiological regulation of vascular tone and the structural transformation of the vessel under pathological conditions. Under physiological conditions, endothelial cells continuously secrete nitric oxide (NO), which relaxes smooth muscle cells and ensures vessel patency. Damage...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199700531-00003

    authors: Haller H

    更新日期:1997-01-01 00:00:00

  • Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

    abstract::Since an earlier review in the Journal substantial additional data have accumulated, further clarifying the in vitro activity, pharmacokinetic profile, clinical efficacy and tolerability of teicoplanin. Recent therapeutic trials confirm the efficacy of teicoplanin in the treatment of microbiologically confirmed Gram-p...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199447050-00008

    authors: Brogden RN,Peters DH

    更新日期:1994-05-01 00:00:00

  • Albumin-bound Paclitaxel: in metastatic breast cancer.

    abstract::A new formulation of paclitaxel, 130-nanometre albumin-bound paclitaxel (nab-paclitaxel), solubilises hydrophobic paclitaxel and may increase paclitaxel delivery to tumour cells. Intravenous nab-paclitaxel 260 mg/m(2) had a higher maximum whole-blood concentration, shorter time to peak concentration, larger distributi...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-200666070-00007

    authors: Robinson DM,Keating GM

    更新日期:2006-01-01 00:00:00

  • Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.

    abstract::Bisoprolol is a beta 1-adrenoceptor antagonist with no partial agonist (intrinsic sympathomimetic) activity or membrane stabilising (local anaesthetic) activity. The oral bioavailability of bisoprolol is high (90%) and the drug has a long elimination half-life which allows once-daily administration; in addition, it is...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198836030-00002

    authors: Lancaster SG,Sorkin EM

    更新日期:1988-09-01 00:00:00

  • Alprazolam: a review of its pharmacodynamic properties and efficacy in the treatment of anxiety and depression.

    abstract::Alprazolam is a triazolobenzodiazepine which is related to diazepam and other 1,4-benzodiazepines, and has a similar pharmacological profile. Relative to the newer benzodiazepines, alprazolam has an intermediate half-life of 10 to 12 hours in healthy young subjects. In placebo-controlled and double-blind comparative t...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,评审

    doi:10.2165/00003495-198427020-00002

    authors: Dawson GW,Jue SG,Brogden RN

    更新日期:1984-02-01 00:00:00

  • Orlistat: in the prevention and treatment of type 2 diabetes mellitus.

    abstract::Orlistat is a nonsystemically acting gastric and pancreatic lipase inhibitor that limits the absorption of dietary fat. A retrospective pooled analysis of three 2-year, double-blind, randomised, placebo-controlled trials involving patients with obesity revealed that orlistat recipients were more likely to experience a...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161140-00011

    authors: Keating GM,Jarvis B

    更新日期:2001-01-01 00:00:00

  • Correction to: Pexidartinib: First Approval.

    abstract::The original article has been corrected. ...

    journal_title:Drugs

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40265-020-01280-5

    authors: Lamb YN

    更新日期:2020-03-01 00:00:00

  • Practical aspects of the use of amiodarone.

    abstract::Amiodarone is a class III antiarrhythmic drug with sympatholytic properties, which prolongs the refractory period of all cardiac tissues, depresses sinus node automaticity and atrioventricular nodal conduction. It is active on all cardiac arrhythmias, its use being limited by the risk of side effects, mainly extracard...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199100412-00009

    authors: Puech P

    更新日期:1991-01-01 00:00:00

  • Clinical aspects of invasive candidiasis in critically ill patients.

    abstract::Invasive candidiasis has emerged as an important cause of morbidity and mortality in intensive care unit patients. This short review focuses on many aspects of Candida infection in critically ill patients including epidemiology, impact on mortality, problems related to diagnosis, strategies to identify patients at ris...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11315590-000000000-00000

    authors: Pennisi M,Antonelli M

    更新日期:2009-01-01 00:00:00

  • Quinidine and digoxin. An important interaction.

    abstract::An increase in serum digoxin concentration occurs in 90% of patients given quinidine. On average, the serum digoxin doubles during treatment with therapeutic doses of quinidine. Almost every patient treated with quinidine will have a decrease in the renal clearance of digoxin and many will have a decrease in the volum...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198224030-00003

    authors: Bigger JT Jr,Leahey EB Jr

    更新日期:1982-09-01 00:00:00